What is Marinus Pharmaceuticals?
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development of ganaxolone, a positive allosteric modulator of GABAA receptors. The company's research focuses on a well-characterized target in the brain known for its anti-seizure, anti-depressant, and anti-anxiety properties. By developing ganaxolone in multiple dose forms—including intravenous, capsule, and liquid—Marinus aims to maximize therapeutic efficacy in both acute and chronic care settings. The company is currently engaged in pivotal studies for conditions such as CDD, postpartum depression, and refractory status epilepticus, positioning itself as a key player in the precision neurology market.
How much funding has Marinus Pharmaceuticals raised?
Marinus Pharmaceuticals has raised a total of $360.2M across 11 funding rounds:
Series C
$21M
Stock Offering
$41.3M
Stock Offering
$27.7M
Stock Offering
$40.3M
Stock Offering
$45M
Stock Offering
$70M
Other Financing Round
$30M
Other Financing Round
$32.5M
Series C (2013): $21M featuring Domain Associates, Canaan Partners, RusnanoMedInvest, Sofinnova Ventures, and Foundation Medicine
Stock Issuance/Offering (2014): $41.3M backed by Undisclosed
Stock Issuance/Offering (2015): $27.7M with participation from Undisclosed
Stock Issuance/Offering (2017): $40.3M led by Bain Capital
Stock Issuance/Offering (2018): $45M supported by Undisclosed
Stock Issuance/Offering (2019): $70M featuring Undisclosed
Other Financing Round (2022): $30M backed by Oaktree
Other Financing Round (2022): $32.5M with participation from Morgan Stanley and H.C. Wainwright & Co.
Key Investors in Marinus Pharmaceuticals
Domain Associates
An investment advisory firm established in 1985, specializing in biotech investments with a track record of supporting numerous IPOs and M&A events.
Canaan Partners
An early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages.
Sofinnova Ventures
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
What's next for Marinus Pharmaceuticals?
With the recent strategic investment, Marinus Pharmaceuticals is well-positioned to accelerate its clinical development programs and prepare for potential commercialization milestones. The company's focus remains on executing its pivotal studies and expanding the clinical utility of ganaxolone. As the firm transitions into a more mature operational phase, the emphasis will likely shift toward regulatory filings and market access strategies. The continued support from institutional investors provides the necessary runway to sustain long-term research initiatives and maintain its competitive edge in the biopharmaceutical landscape, ensuring that its innovative treatments reach patients in need of effective, convenient therapeutic options.
See full Marinus Pharmaceuticals company page
